Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment

Epidemiological trends and clinical characteristic of NAFLD/MAFLD in Asia

“…5 In a multicenter prospective study from China, biopsy-proven NASH was found to be 18.2% in 1000 treatment-naïve CHB patients with significant fibrosis. 21 (anti-HBc) was linked to lower steatosis grade but higher fibrosis stage. 22 During a mean follow-up of 6 years, NAFLD patients with positive anti-HBc had a higher incidence of HCC or cirrhosisrelated complications.…”

“…Since risk factors for fatty liver in CHB patients are attributed to metabolic dysfunction, which is the same as NAFLD in the general population, the coexisting fatty liver in patients with CHB is thus regarded as NAFLD 5 . In a multicenter prospective study from China, biopsy‐proven NASH was found to be 18.2% in 1000 treatment‐naïve CHB patients with significant fibrosis 21 . After a 72‐week entecavir treatment, 42.7% of patients had resolution of NASH without fibrotic progression at the second biopsy, and 3.7% of patients who did not have NASH at baseline developed NASH.…”

Metabolic dysfunction-associated fatty liver disease: from basic research to clinical application

“…In Chang and colleagues’ multi-center, prospective study of 1000 treatment-naïve patients with biopsy-confirmed CHB, NASH was found in 182 patients (18.2%), 46% of these achieved resolution of NASH, and only 4% of the patients developed new-onset NASH after 72 weeks of entecavir treatment. Body mass at baseline and a slight weight change during follow-up were associated with the prevalence, incidence, and remission of NASH in patients with CHB [13] . Finally, steatosis is more prevalent in patients with CHB and is a common reason for abnormal circulating liver enzyme activities in infected patients with a low HBV-DNA load or a good response to infection.…”

“…Body mass at baseline and a slight weight change during follow-up were associated with the prevalence, incidence, and remission of NASH in patients with CHB. [ 13 ] Finally, steatosis is more prevalent in patients with CHB and is a common reason for abnormal circulating liver enzyme activities in infected patients with a low HBV-DNA load or a good response to infection.…”

Association between nonalcoholic fatty liver disease status changes and antiviral efficacy in chronic hepatitis B

“…Additional studies have shown that antiviral therapy may affect the development of NAFLD. Chang et al 14 reported that the incidence of new-onset NAFLD was 50/1000 person-years in patients treated with entecavir, almost two times that in the general population. 15,16 Our previous study found that the longer the duration of antiviral therapy, the higher the incidence of NAFLD.…”